ERBB2 and neoplasm: They then discuss about the role of immunotherapy in this field, based on the results from the CHECKMATE 577 trial, and the use of biomarkers, such as human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1), circulating tumour DNA (ctDNA) and microsatellite status.